s part of our focus to better understand cancer biology and the intersection with the immune system, we’ve partnered with Scientific American to underwrite an editorial series highlighting emerging trends in I-O, with a particular focus on biomarkers. The series, which kicked off during the Society for Immunotherapy of Cancer 32^nd Annual Meeting, will feature perspectives from Bristol-Myers Squibb researchers on the latest challenges and discoveries in I-O.